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Neurofibromatosis type 1 (NF1), a common autosomal dominant disorder caused by loss of the NF1 gene, is characterized clinically by neurofibromas and more rarely by neurofibrosarcomas (1) (2) (3) . Abnormalities in Schwann cells are thought to be responsible for both types of tumors (4, 5) . Whereas the basis of the Schwann cell as the affected cell is not well understood, the underlying mechanism of transformation for both tumors is through the Ras signaling pathway. Neurofibromin, the protein encoded by NF1, possesses an intrinsic GTPase accelerating activity for the Ras proto-oncogene. Through this activity it is a negative regulator of Ras. Thus, loss of neurofibromin causes elevated levels of activated Ras, which leads to hyperactivation of downstream signals (6) (7) (8) (9) (10) .
The best characterized Ras signals are through the mitogenactivated protein (MAP) kinase cascade. Ras binds and activates the serine͞threonine kinase Raf, which leads to sequential activation of the MEK and ERK kinases (11) . Ras also activates another MAP kinase family member, jun-N-terminal kinase (JNK), through a Raf-independent mechanism that is not well defined but known to require the small G proteins Rac and Cdc42 (12, 13) .
A candidate for an effector of Rac is the serine͞threonine kinase Pak (p65 pak ) because it binds Rac, stimulates JNK, and can induce changes in the actin cytoskeleton similar to those induced by activated Ras and Rac (14) (15) (16) (17) (18) (19) . In yeast, members of the Rho͞Rac family participate in Ras signaling (20) , and the Pak homolog Ste20 mediates a signal required for filamentous growth through a RasϾCdc42ϾSte20 cascade (21) .
These observations prompted us to determine whether Pak is required for Ras signaling in Schwann cells. We found that dominant negative mutants of Pak1 (Pak1 R299 ) specifically inhibited transformation by Ras of a rat Schwann cell line and markedly reduced the tumorigenic capacity of a neurofibrosarcoma cell line from an NF1 patient. Surprisingly, transformation inhibition correlated with ERK inhibition but not JNK inhibition. These observations suggest that a functional connection between Pak and ERK mediates a signal essential for Ras transformation.
MATERIALS AND METHODS
Plasmids. cDNA expression plasmids using the CMV promoter to express myc-tagged Pak1 and Pak1 R299 based on the plasmid pCMV6M (a modified version of pCMV5) have been described elsewhere (22) . Human K-ras4B expression systems that use pZIP-NeoSV(x)1, a retrovirus vector (neomycin resistant) were a gift from C. Der (University of North Carolina, Chapel Hill) Expression of the inserted gene is regulated from the Moloney long terminal repeat promoter. v-Raf, Rac, JNK, and ERK plasmids have been described elsewhere (23) .
Cell Culture and Transformation Assays. Schwann cells and ST88-14 cells were obtained from Thomas Glover, University of Michigan (8, 24) . Schwann cells were grown in high glucose (4.5 g͞liter) Mediatech DMEM purchased from Fisher Scientific, supplemented with 10% heat inactivated fetal bovine serum (Sigma), penicillin (100 units͞ml), streptomycin (100 mg͞ml), and 100 M ZnCl 2 , and kept at 37°C and 5% CO 2 ͞95% air. ST88-14 cells were grown in RPMI 1640 purchased from Fisher Scientific, supplemented with 15% fetal bovine serum (Sigma), penicillin (100 units͞ml), and streptomycin (100 mg͞ml), and kept at 37°C and 5% CO 2 ͞95% air. DNA transfections were performed by the calcium phosphate precipitation technique. Twenty micrograms total DNA (6.5 g of each test DNA plus 7 g of Pak DNA and the appropriate amount of pUC19 plasmid to bring the total to 20 g) were mixed briefly with 0.5 ml of 0.25 M CaCl 2 and 0.5 ml of 2ϫ N,N-bis(2-hydroxethyl)-2-aminoethanesulfonic acid (BES)-buffered saline and incubated 10-20 min at room temperature. The mixture was then added dropwise to a 50-60% confluent, freshly fed 100-mm dish of cells, swirled gently, and incubated 18-24 h at 37°C and 5% CO 2 . Cells were
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washed twice with growth media, refed, and incubated for 24-48 h. Soft agar assays were performed as described (25) . The 10 5 post-transfection cells were plated on 60-mm dishes. After 21-24 days, colonies were scored by inspection under a Nikon DIAPhot microscope using phase contrast and by staining the dishes with 0.5 g͞ml MTT (Sigma) overnight at 37°C. Transfection efficiency assays using pRSV as a ␤-galactosidase reporter have been described (23) . Transfection efficiencies ranged from 1% to 3% and were not affected by any of the plasmids used in this study. , each construct was cotransfected with pCDNA3 into Schwann cells or ST88-14 cells. DOTAP liposomal transfections were performed according to manufacturer's protocol (Boehringer Mannheim). A total of 5 g of DNA (4.5 g of Pak and 0.5 g of PCDNA3) and 40 l of DOTAP reagent (g͞l) were added to a 100-mm dish containing 3 ml of Opti-MEM (Life Technologies, Grand Island, NY). After 4-5 h, 7 ml of growth medium was added. Cells were split and plated on another dish 48-72 h after the addition of DNA. The transfected cells were selected in growth medium containing 400 g͞ml (for ST88-14 cells) or 500 g͞ml (for Schwann cells) of Geneticin (G418; GIBCO͞BRL). Protein expression levels were determined by Western blot (immunoblot) analysis of G418-selected cell lysates using the anti-myc tag mAb 9E10 (Calbiochem) or anti-ERK antibodies (New England Biolabs). Blots were visualized with the procedure outlined in the enhanced chemiluminescence kit (Amersham).
JNK and MAP͞ERK Kinase Assays. Transfections of Schwann cells were performed with DOTAP liposomal transfections. A total of 5 g of DNA (1 g of HA-JNK1 or HA-ERK1, 2 g of each test DNA; when single plasmids were tested, and 2 g of pUC19 plasmid) and 40 l of DOTAP reagent were added to a 10-cm dish containing 3 ml of Opti-MEM. After 4-5 h, 7 ml of fresh growth medium was added. Approximately 48-72 h after addition of DNA, cells were washed with cold PBS and lysed in 40 mM Hepes (pH 7.4), 1% Nonidet P-40, 100 mM NaCl, 1 mM EDTA, 25 mM NaF, 1 mM sodium orthovanadate, 10 g͞ml leupeptin, and 10 g͞ml aprotinin, and centrifuged at 12,000 ϫ g for 25 min at 4°C (15) . Extracts were incubated with HA-antibody (12CA5) and protein A beads for 3-3.5 h at 4°C. Precipitates were washed three times with lysis buffer and washed two times in 2X phosphorylation buffer. The precipitates were then incubated with 5 g of GST-c-jun (for Jun kinase) or myelin basic protein (for ERK), 10 Ci of [␥- Subcutaneous Tumor Xenografts. ST88-14 xenografts were derived from in vitro cell cultures using described methods (26) . Log-phase cells grown in RPMI 1640 and 15% fetal bovine serum were harvested by trypsinization, washed, and centrifuged into a pellet. The cell pellet was resuspended in sterile 0.9% saline and Matrigel (Collaborative Biomedical Products, Bedford, MA). Aliquots were injected s.c. into the right flank of each nude mouse. Mice were observed for the appearance of nodular tumor growth. When the perpendicular diameter of each tumor reached 2 mm, the length and width of s.c. xenografts were measured every 3-4 days with vernier calipers (Manostat, New York). Tumor volume was calculated by the following formula: width 2 ϫ length͞2.
RESULTS
To evaluate the roles of Rac and Pak in Schwann cell transformation, we transfected Rac L61 into MT4H1, a T antigen-immortalized Schwann cell line known to be sensitive to Ras transformation, and then determined whether the transfected cells grew in soft agar (24, 27 , a dominant negative mutant of Rac, inhibited transformation by Ras but not v-Raf, an oncogenic mutant ( Fig. 1 b and c) , which lacks kinase activity, inhibited Ras transformation by Ϸ80% (Fig. 1b) . Pak1 R299 also inhibited Rac͞Raf cooperation (data not shown). This mutant was not a general inhibitor of cell transformation because it failed to inhibit transformation by v-Raf, an oncogenic Raf mutant (Fig. 1c) . To determine whether the inhibition we observed was caused by sequestering Rac͞Cdc42, we tested inhibition by Pak1 L83,L86,R299 , a mutant that lacks kinase activity and also fails to bind either Rac or Cdc42 (Fig. 1b) . Pak1
was an equally effective inhibitor of Ras transformation as Pak1 R299 , suggesting that Pak binds additional targets essential for Ras signaling, distinct from Rac and Cdc42. Ras was expressed at comparable levels in all transfections, as determined by Western blotting experiments (data not shown), suggesting that Pak mutants did not affect Ras expression.
We also developed rat Schwann cell lines that expressed similar levels of the various Pak mutants. As expected from the results described above, the cell line expressing the hyperactive Pak1 L83,L86 showed no effects on transformation, and cell lines expressing the two dominant negative Pak mutants were highly resistant to transformation by Ras (Fig. 1d) . Again, inhibition of transformation was not seen when v-Raf was substituted for Ras. These results suggest an essential role for Pak in Ras transformation of rat Schwann cells, although Pak itself is not an oncogene.
Two MA P kinases are activated by Ras, ERK, (RasϾRafϾMEKϾERK) and JNK (RasϾRacϾPakϾ MEKKϾSEKϾJNK) (11) . Whereas in most experimental systems Rac and Pak only activate JNK, under some conditions they also activate ERK (18, 29, 30) . Such alternative inputs are to be required likely to maintain prolonged ERK activation (31) . To determine the effect of Pak mutants on downstream Ras effector pathways for Rac and Ras, we measured kinase activities after cotransfection with the various plasmids (Fig.  2) . K-Ras, Rac L61 , and Pak1 (Fig. 2 b-d) . When the four Pak mutants were tested in this assay, we observed that Pak1 and Pak1 L83,L86 had no effect on ERK activity either by themselves or together with Ras (Fig. 2b) or v-Raf (Fig. 2d) . However, Rac , both stimulated ERK activation by Raf D340 , the partially activated Raf mutant (Fig.  2c) . When we tested the two kinase-deficient mutants Pak1 , we found they inhibited Ras activation of ERK by 66 and 57%, respectively (Fig. 2b) (data not shown). Neither Pakdominant negative mutant inhibited ERK activation by Raf (Fig.  2d) . Thus, in all of the cases where Pak inhibited Ras transformation and Rac͞Raf cooperative transformation, Pak also inhibited ERK activation.
The experiments described so far used rat Schwann cells immortalized with T-antigen (24) , and the results were consistent with those we recently observed in the Rat-1 cell line (23) . However, we have not demonstrated a role for Pak in NIH 3T3 cell transformation. To test the validity of the rat cell systems for evaluating the role of Pak in human neurofibrosarcomas, we determined the effects of Pak mutants on the ST88-14 cell line. This cell line was derived from a neurofibrosarcoma that developed in an NF1 patient. ST88-14 cells have reduced levels of neurofibromin, which leads to elevated levels of Ras-GTP. Furthermore, its transformed phenotype is reverted by expression of GAP or blocking Ras processing with farnesyl transferase inhibitors (8, 32) . We made stable cell lines of ST88-14 expressing the various Pak mutants, confirmed expression through Western blots, and then tested for maintenance of the transformed phenotype (Fig. 3a) . We also observed that levels of phosphorylated ERK were reduced in extracts from cells expressing the dominant negative Pak mutants although the levels of total ERK were not affected (Fig. 3b) . Cells expressing the dominant negative Pak constructs were reduced in their soft agar plating efficiency by Ϸ80% (Fig. 3c) .
To (Fig. 4a) . The mean tumor volume-doubling time was reduced to 28% and 24.5% for Pak1 , respectively, when compared with wild-type ST88-14 tumor growth. Histological examination of wild-type ST88-14 s.c. tumors showed spindle-shaped cells arranged in whorls and linear bands and a large number of mitotic figures (Fig. 4b ). Pak1 and Pak1 L83,L86 transfectants showed a relative preservation of the wild-type ST88-14 morphology and arrangement (Fig. 4 c and d) . However, dominant negative Pak tumors showed a comparative increase in cytoplasmic volume, dispersed nuclear chromatin, a loss of fibrosarcomatous architectural organization, and few mitotic figures (Fig. 4 e and  f ) . The experiments with ST88-14 cells correlated with those experiments described above with the rat Schwann cells, suggesting that Ras transformation of rat Schwann cells is an appropriate model system to study the role of Pak in neurofibrosarcomas.
DISCUSSION
Our data show that activated Pak is not an oncogene in Schwann cells; however, because mutants lacking kinase activity inhibit Ras transformation, Pak interacts with essential Ras signaling molecules. There are likely to be multiple Ras signaling proteins that Pak binds because a dominant negative Pak that fails to bind either Cdc42 or Rac is as effective at inhibiting cell transformation as one that binds. Our study uses dominant negative mutants, which are not true knockouts of Pak, and they may act through nonphysiological interactions and not by interfering with endogenous Pak. However, the observation that there are multiple interactions between Pak and Ras signaling components strengthens the conclusion that Pak itself mediates a signal essential for Ras transformation. Our studies also suggest that the relevant signal responsible for transformation inhibition is from Ras to ERK because both mutants that inhibit transformation also inhibit Ras activation of ERK; whereas, JNK activation only is inhibited with the mutant that binds Cdc42 and Rac. (30, 33) . In addition, we observe coactivation of ERK when activated Raf is cotransfected with activated Pak (Fig. 2c) . Putting all of these data together, we propose that there is a RacϾPakϾERK signal that is essential to maintain ERK activation and Ras transformation. The signal from Pak to ERK may be mediated through various intermediates such as MEK or Raf because both are stimulated and phosphorylated by Pak (33) . There is also a RasϾRacϾPakϾJNK signal, but because Pak L83,L86,R299 does not inhibit Ras or Rac activation of JNK (Fig. 2a) , it is likely that Rac uses other effectors as well as Pak to activate JNK. Another way Pak may affect Ras transformation is through the actin cytoskeleton. Activated Pak mutants can alter the 
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Proc. Natl. Acad. Sci. USA 95 (1998) actin cytoskeleton by inducing ruffling and disassembling stress fibers (22, 34) . Both of these events are similar to those induced by activated Ras (35, 36) . Our data suggest that blocking these actin events also may contribute to cell reversion in Schwann cells because nude mice xenografts of a neurofibrosarcoma expressing the dominant negative Paks lose their basic sarcoma architecture (Fig. 4) . Our previous study demonstrated that Pakdominant negative mutants inhibited Ras transformation in Rat-1 cells, but because the mutants had no effect on Ras transformation in NIH 3T3 cells, it was not clear that the observation could be extended to other cell systems (23) . The reason that Pak failed to effect Ras transformation in the NIH 3T3 cells remains unclear, but one possibility is that NIH 3T3 cells rely more heavily on the Ras͞Raf͞ERK cascade than other cells; another possibility is that our Pak expression systems do not express Pak at levels sufficient to sequester interacting proteins. We favor the latter possibility because there is a well-documented role of Rac in NIH 3T3 cell transformation, suggesting that Pak R299 should inhibit transformation by sequestering Rac. Here, we report Pak-dominant negative mutants inhibit Ras transformation and ERK activation in two additional cell systems relevant to Ras-sensitive tumors. Furthermore, the sensitivity of an NF1 neurofibrosarcoma to Pak-dominant negative mutants suggests that Pak may be a target for novel antineoplastic drugs useful for treating Ras-dependent tumors (37) .
